Gastroesophageal Reflux Disease Clinical Trial
Official title:
A Multicenter, Double-Blind, Randomized Trial of the Relationship of Intragastric Acid Control and Healing Status of Moderate and Severe Erosive Esophagitis After Treatment With Esomeprazole Magnesium (NEXIUM®) 10 mg and 40 mg Once Daily
Verified date | March 2009 |
Source | AstraZeneca |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and 40 mg once daily.
Status | Completed |
Enrollment | 120 |
Est. completion date | August 2005 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Male or non-pregnant, non-lactating female patients between the ages of 18 and 75 years - Patients must have moderate to severe erosive esophagitis Exclusion Criteria: - Significant gastrointestinal bleeding - Severe heart, lung, liver or kidney disease - Esophagitis not related to acid reflux |
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind
Country | Name | City | State |
---|---|---|---|
United States | Research Site | Alabaster | Alabama |
United States | Research Site | Anaheim | California |
United States | Research Site | Baltimore | Maryland |
United States | Research Site | Bellevue | Washington |
United States | Research Site | Bridgeport | Connecticut |
United States | Research Site | Brooklyn | New York |
United States | Research Site | Chapel Hill | North Carolina |
United States | Research Site | Chevy Chase | Maryland |
United States | Research Site | Covington | Louisiana |
United States | Research Site | Dallas | Texas |
United States | Research Site | Decatur | Georgia |
United States | Research Site | Dinuba | California |
United States | Research Site | Duncansville | Pennsylvania |
United States | Research Site | Egg Harbor Township | New Jersey |
United States | Research Site | Fort Lauderdale | Florida |
United States | Research Site | Fresno | California |
United States | Research Site | Hialeah | Florida |
United States | Research Site | Jacksonville | Florida |
United States | Research Site | Jacksonville | North Carolina |
United States | Research Site | Kalamazoo | Michigan |
United States | Research Site | Knoxville | Tennessee |
United States | Research Site | Louisville | Kentucky |
United States | Research Site | Miami | Florida |
United States | Research Site | Milwaukee | Wisconsin |
United States | Research Site | N Providence | Rhode Island |
United States | Research Site | New Port Richey | Florida |
United States | Research Site | New York | New York |
United States | Research Site | Oakbrook Terrace | Illinois |
United States | Research Site | Ogden | Utah |
United States | Research Site | Orange | California |
United States | Research Site | Passaic | New Jersey |
United States | Research Site | Pittsburgh | Pennsylvania |
United States | Research Site | Rome | Georgia |
United States | Research Site | San Diego | California |
United States | Research Site | Savannah | Georgia |
United States | Research Site | Spokane | Washington |
United States | Research Site | Troy | Michigan |
United States | Research Site | Urbana | Illinois |
United States | Research Site | Zephyr Hills | Florida |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine the relationship between 24-hour intragastric pH at Day 5 and healing status of moderate to severe erosive esophagitis, after 4 weeks of treatment with 2 doses of esomeprazole magnesium. | |||
Secondary | Secondary outcomes and the relationship to pH will also be assessed. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02135107 -
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
|
Phase 3 | |
Completed |
NCT01432392 -
Symptom Control and Impact on Daily Life in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Recruiting |
NCT01249482 -
Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
|
N/A | |
Completed |
NCT01578642 -
Feasibility Study for Evaluating the Effect of Electrical Stimulation on Lower Esophageal Sphincter Pressure and Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease
|
Phase 2 | |
Completed |
NCT01200550 -
The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients
|
N/A | |
Unknown status |
NCT01128608 -
The Effect of High PCO2 Solution on Esophageal Acid Sensation
|
N/A | |
Completed |
NCT00978016 -
A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)
|
Phase 2 | |
Completed |
NCT00998244 -
Study to Evaluate the Effect of a Very Low Carbohydrate Diet on Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT00768443 -
Symptoms and Management Strategies in Gastroesophageal Reflux Disease (GERD)
|
N/A | |
Completed |
NCT00768196 -
Prevalence of EED and Quality of Life Evaluated by Gastroesophageal Reflux Disease (GERD)-Q in Korean GERD Patients
|
N/A | |
Recruiting |
NCT00498082 -
Determinants of Efficacy of EsophyX Treatment in Gastro-Esophageal Reflux Disease
|
N/A | |
Completed |
NCT00886197 -
Diagnostic Efficacy of Narrow Band Imaging in Patients With Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT00378898 -
Feasibility of Placing Bravo PH Capsule in Proximal Esophagus
|
N/A | |
Completed |
NCT00217347 -
Evaluation of Efficiency of Esophageal Capsule Endoscopy in the Screening of Patients With Gastroesophageal Reflux Disease or Dyspepsia as Compared to Upper Endoscopy
|
N/A | |
Completed |
NCT00507377 -
Foreshortened Esophagus and Its Surgical Therapy
|
||
Completed |
NCT00165022 -
Development of a Novel Disease-Specific Quality of Life Questionnaire for Gastroesophageal Reflux Disease (GERD) Patients in Chinese Population
|
N/A | |
Completed |
NCT00625495 -
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
|
Phase 4 | |
Completed |
NCT00214552 -
Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma.
|
Phase 3 | |
Completed |
NCT00618150 -
Patient Education in Gastroesophageal Reflux Disease
|
N/A | |
Completed |
NCT03299985 -
Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease
|
N/A |